HOME > TOP STORIES

TOP STORIES

BUSINESS Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.

April 8, 2014
BUSINESS India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard

April 7, 2014
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe

April 4, 2014
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial

April 3, 2014
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments

April 2, 2014
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills

April 1, 2014
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug

April 1, 2014
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.

March 31, 2014
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market　

March 31, 2014
ORGANIZATION JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products

March 28, 2014
ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014

March 27, 2014
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho

March 26, 2014
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan

March 26, 2014
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates

March 25, 2014
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting

March 24, 2014
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J

March 24, 2014
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year

March 20, 2014
BUSINESS Eli Lilly Japan Sales Up 9% in 2013

March 19, 2014
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal

March 18, 2014
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis

March 17, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…